https://www.biospace.com/nervgen-pharma-launches-multiple-sclerosis-program-targeting-nerve-remyelination
Nervgen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination - BioSpace
Jun 27, 2019 - Lead indication for spinal cord injury continues to advance to phase one clinical trial
multiple sclerosis programpharmalaunchestargetingnerve